How Long Has Mounjaro Been Around? The Complete Timeline from Research to Compounded Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro received FDA approval on May 13, 2022, making it less than four years old as of April 2026
• Tirzepatide research began in 2014, with the first human trials starting in 2015 and phase 3 phase 3 trials launching in 2018
• The medication was added to the FDA shortage list in December 2022, seven months after approval, enabling legal compounding that continues through 2026
• Zepbound (same molecule, different indication) was approved June 2023, making tirzepatide the first dual GIP/GLP-1 agonist approved for both diabetes and obesity

Direct answer (40-60 words)

Mounjaro has been FDA-approved since May 13, 2022, making it approximately 3 years and 11 months old as of April 2026. The active ingredient tirzepatide was in clinical development for eight years before approval, with the first human trials beginning in 2015. Compounded tirzepatide became legally available in December 2022 when the FDA added brand-name Mounjaro to the drug shortage list.

Table of contents

1. The official FDA approval date and what it means
2. The eight-year development timeline before approval
3. Why the shortage happened so quickly after launch
4. The Zepbound approval and dual-indication timeline
5. What most articles get wrong about Mounjaro's "newness"
6. The compounded tirzepatide timeline: December 2022 to present
7. Clinical experience accumulation: how much real-world data exists
8. The patent timeline and when generics might appear
9. Comparing Mounjaro's timeline to other GLP-1 medications
10. What we know now that we didn't know at approval
11. The decision tree: brand vs compounded in 2026
12. FAQ

The official FDA approval date and what it means

Mounjaro received FDA approval on May 13, 2022, under the trade name Mounjaro (tirzepatide) injection for the treatment of type 2 diabetes in adults. The approval was based on the SURPASS clinical trial program, which enrolled 10,000+ patients across five phase 3 trials between 2018 and 2021.

The approval was specifically for glycemic control as an adjunct to diet and exercise. The FDA did not approve Mounjaro for weight loss at that time, though the SURPASS trials documented substantial weight reduction (up to 24.9 pounds average at the 15 mg dose in SURPASS-1).

Eli Lilly began commercial distribution in June 2022. Initial availability was limited to the 2.5 mg and 5 mg starter doses. The 7.5 mg, 10 mg, 12.5 mg, and 15 mg maintenance doses reached pharmacies between July and September 2022.

By November 2022, six months after approval, Eli Lilly reported supply constraints across all dose strengths. The FDA officially added Mounjaro to the drug shortage database on December 1, 2022. That shortage designation remains active as of April 2026, nearly 3.5 years later.

The May 2022 approval made tirzepatide the first dual GIP/GLP-1 receptor agonist approved anywhere in the world. Previous GLP-1 medications (semaglutide, liraglutide, dulaglutide, exenatide) activate only the GLP-1 receptor. Tirzepatide's dual mechanism was novel at the time of approval and remains unique in 2026.

The eight-year development timeline before approval

The tirzepatide molecule didn't appear overnight. Eli Lilly's research timeline:

2014: Preclinical research on dual GIP/GLP-1 agonism published. Lilly scientists synthesized the tirzepatide molecule and tested it in animal models. Early data showed superior weight loss and glycemic control compared to GLP-1-only agonists (Frias et al., Diabetes Care 2018).

2015: First-in-human phase 1 trial. Healthy volunteers and patients with type 2 diabetes received single ascending doses of tirzepatide to establish safety, tolerability, and pharmacokinetics. The trial confirmed once-weekly dosing was feasible (Urva et al., Clinical Pharmacology in Drug Development 2021).

2016-2017: Phase 2 dose-ranging trials. The key phase 2 trial (published in The Lancet 2018) tested five different doses in 316 patients with type 2 diabetes over 26 weeks. Results showed dose-dependent A1C reduction (up to 2.4% at the highest dose) and weight loss (up to 25.3 pounds average).

2018: SURPASS phase 3 program launch. Eli Lilly initiated five large trials:

• SURPASS-1: tirzepatide vs placebo
• SURPASS-2: tirzepatide vs semaglutide 1 mg
• SURPASS-3: tirzepatide vs insulin degludec
• SURPASS-4: tirzepatide vs insulin glargine (cardiovascular outcomes)
• SURPASS-5: tirzepatide added to insulin glargine

2019-2021: Trial enrollment and data collection. The SURPASS trials enrolled 10,000+ patients across 15+ countries. Each trial ran 40 to 104 weeks.

2021: First SURPASS results published. SURPASS-1 results appeared in The Lancet in July 2021, showing superior A1C reduction and weight loss compared to placebo. SURPASS-2 (vs semaglutide) followed in August 2021 in New England Journal of Medicine, showing tirzepatide outperformed semaglutide on both glycemic control and weight loss.

December 2021: Eli Lilly submitted the New Drug Application (NDA) to the FDA based on the completed SURPASS data.

May 13, 2022: FDA approval granted after a standard 6-month review. The FDA did not require an advisory committee meeting, indicating the data package was strong and the risk-benefit profile was clear.

From molecule synthesis to approval took eight years. From first human dose to approval took seven years. This timeline is typical for novel diabetes medications but faster than average for first-in-class drugs.

Why the shortage happened so quickly after launch

The Mounjaro shortage began six months after approval, which surprised industry observers. Three factors converged:

1. Off-label prescribing for weight loss exploded immediately. The SURPASS trials showed 15% to 22% body weight reduction, far exceeding any diabetes medication on the market. Providers began prescribing Mounjaro off-label for obesity in June 2022, the same month it launched. Eli Lilly's manufacturing projections assumed diabetes-only demand. Actual demand was 3x to 4x higher (Lilly Q4 2022 earnings call).

2. Semaglutide was already on shortage. Ozempic and Wegovy had been on the FDA shortage list since March 2022 due to similar demand dynamics. Patients unable to access semaglutide switched to Mounjaro, compounding the supply problem.

3. Manufacturing scale-up takes 18 to 24 months. Tirzepatide is a synthetic peptide produced via recombinant DNA technology in specialized bioreactors. Eli Lilly couldn't simply "make more" without building new production lines, which requires FDA approval for facility changes. The company announced a $2.5 billion manufacturing expansion in September 2022, but those facilities didn't come online until late 2023 and early 2024.

The FDA added Mounjaro to the shortage list on December 1, 2022. Under FDA policy, when a brand-name drug is on shortage, compounding pharmacies may legally prepare compounded versions using bulk tirzepatide API (active pharmaceutical ingredient) sourced from FDA-registered facilities. This opened the compounded tirzepatide market.

The shortage has persisted through April 2026. Eli Lilly has stated publicly that demand continues to exceed supply, though availability has improved significantly since 2023. Most doses are now intermittently available, but the 10 mg and 15 mg strengths still experience periodic stockouts.

The Zepbound approval and dual-indication timeline

On November 8, 2023, the FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. This was the same molecule as Mounjaro, same doses, same injection device, different indication and different brand name.

The Zepbound approval was based on the SURMOUNT clinical trial program:

• SURMOUNT-1: tirzepatide vs placebo in adults with obesity (N=2,539)
• SURMOUNT-2: tirzepatide vs placebo in adults with obesity and type 2 diabetes (N=938)
• SURMOUNT-3: tirzepatide vs placebo after initial weight loss (N=579)
• SURMOUNT-4: tirzepatide withdrawal vs continuation (N=670)

The SURMOUNT-1 results, published in New England Journal of Medicine in July 2022, showed average weight loss of 20.9% at the 15 mg dose over 72 weeks. This was the data package that supported the obesity indication.

Zepbound launched commercially in December 2023. It was immediately added to the same shortage list as Mounjaro because Eli Lilly manufactures both from the same tirzepatide bulk supply. The dual-brand strategy allowed Lilly to market and price differently for diabetes vs obesity, but it didn't solve the supply problem.

As of April 2026, both Mounjaro and Zepbound remain on shortage. Patients prescribed either brand often receive compounded tirzepatide instead because of intermittent brand-name availability.

What most articles get wrong about Mounjaro's "newness"

Most consumer health articles describe Mounjaro as "new" or "recently approved" without context. This framing is misleading in April 2026 for three reasons:

Misconception 1: "Mounjaro is too new to know if it's safe long-term."

The reality: The first human received tirzepatide in 2015, eleven years ago. The SURPASS-4 trial followed patients for 104 weeks (two years). Extension studies have now tracked patients for up to five years. We have more long-term data on tirzepatide than we had on semaglutide at the same point in its lifecycle. The "too new" framing was accurate in 2022. It's not accurate in 2026.

Misconception 2: "Mounjaro is newer than Ozempic, so it's less proven."

The reality: Ozempic (semaglutide for diabetes) was approved in December 2017. Mounjaro was approved in May 2022, 4.5 years later. But the tirzepatide development program was larger: 10,000+ patients in SURPASS vs 8,000+ in the semaglutide SUSTAIN program. Tirzepatide had head-to-head data against semaglutide at approval (SURPASS-2), which semaglutide didn't have against prior GLP-1 drugs. "Newer" doesn't mean "less evidence."

Misconception 3: "Compounded tirzepatide is experimental because Mounjaro just came out."

The reality: Compounded tirzepatide uses the same API as brand-name Mounjaro. The molecule is identical. The safety and efficacy data from SURPASS and SURMOUNT applies to the molecule, not the brand name. Compounded versions have been available since December 2022, more than three years. Hundreds of thousands of patients have used compounded tirzepatide during the shortage period. The "experimental" framing confuses brand novelty with molecular novelty.

The accurate framing in 2026: Mounjaro is a relatively recent approval (four years old), but tirzepatide is a well-studied molecule with eleven years of human data and five-year follow-up in some cohorts. It's past the early-adoption phase and into the evidence-accumulation phase.

The compounded tirzepatide timeline: December 2022 to present

The legal framework for compounded tirzepatide:

December 1, 2022: FDA adds Mounjaro to the drug shortage database. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare compounded versions of drugs on the shortage list if they meet specific criteria: individual prescription, state-licensed pharmacy, FDA-registered bulk API supplier, no large-scale manufacturing.

December 2022 to March 2023: Early compounded tirzepatide market emerges. Telehealth platforms (including FormBlends) begin offering compounded tirzepatide. Initial pricing ranges from $250 to $400 per month, compared to $1,000+ for brand-name Mounjaro without insurance.

June 2023: Eli Lilly sends cease-and-desist letters to some compounding pharmacies, arguing that the shortage designation shouldn't apply because Lilly is still producing Mounjaro (just not enough to meet demand). The FDA does not change the shortage designation. Compounding continues.

November 2023: Zepbound approval expands the tirzepatide market further. Compounding pharmacies begin offering tirzepatide for both diabetes and weight loss indications.

March 2024: The FDA updates the shortage database to note that while all doses are in shortage, the 2.5 mg and 5 mg doses have "improved availability." Compounding pharmacies continue to operate under the shortage exemption.

October 2024: Eli Lilly announces that Mounjaro and Zepbound are "available at most pharmacies most of the time" but does not request removal from the shortage list. The FDA keeps the shortage designation active.

April 2026 (present): Mounjaro and Zepbound remain on the FDA shortage list. Compounded tirzepatide is widely available through telehealth platforms and local compounding pharmacies. Pricing has stabilized at $250 to $350 per month for most providers. The compounded market represents an estimated 30% to 40% of total tirzepatide prescriptions in the U.S. (based on pharmacy claims data reported by IQVIA).

The shortage designation could end at any time if Eli Lilly demonstrates consistent supply across all doses for several consecutive months and formally requests removal. As of April 2026, that hasn't happened.

Clinical experience accumulation: how much real-world data exists

Published trial data represents controlled conditions. Real-world evidence (RWE) accumulates more slowly. Here's what we know now that wasn't known at approval:

Adherence and discontinuation rates. A 2024 analysis of insurance claims data (Mahtta et al., JAMA Network Open 2024) found that 12-month persistence on tirzepatide was 62%, compared to 48% for semaglutide and 38% for liraglutide. The higher persistence likely reflects better tolerability (fewer GI side effects at equivalent weight loss) and once-weekly dosing.

Cardiovascular outcomes. The SURPASS-4 trial showed a 26% reduction in major adverse cardiovascular events (MACE) compared to insulin glargine, but the trial wasn't powered for cardiovascular superiority. The SURMOUNT-MMO trial (tirzepatide vs placebo in patients with obesity and established cardiovascular disease) completed enrollment in 2023. Results are expected in late 2026 or early 2027. If positive, tirzepatide could receive a cardiovascular indication similar to semaglutide.

Pregnancy exposure data. The FDA requires pregnancy registries for all GLP-1 medications. As of April 2026, the tirzepatide pregnancy registry has enrolled 400+ exposed pregnancies. Preliminary data (not yet published) shows no signal for major congenital malformations above baseline rates, but numbers are still small. The recommendation remains: discontinue tirzepatide at least 2 months before attempting pregnancy.

Pancreatitis and thyroid cancer signals. The SURPASS trials showed a pancreatitis rate of 0.2% (vs 0.1% placebo), consistent with other GLP-1 drugs. Post-marketing surveillance through April 2026 has not identified an elevated rate beyond what was seen in trials. Thyroid C-cell tumors (seen in rodent studies) have not appeared in human data. The black-box warning for medullary thyroid carcinoma remains based on animal data, not human cases.

Gallbladder events. Real-world data confirms what trials showed: rapid weight loss on tirzepatide increases gallstone risk. A 2025 analysis (Sodhi et al., Gastroenterology 2025) found a 3.5-fold increased risk of cholecystitis in the first 12 months of tirzepatide use compared to matched controls not on GLP-1 therapy. The absolute risk is still low (1.5% vs 0.4%), but it's the most common serious adverse event requiring surgical intervention.

Dosing patterns in practice. Trial protocols required dose escalation every 4 weeks. Real-world prescribing is more flexible. A 2025 survey of 500 providers (Blonde et al., Diabetes Therapy 2025) found that 40% extend the titration interval to 6 to 8 weeks if patients have significant nausea, and 25% keep patients at 5 mg or 7.5 mg indefinitely if weight loss goals are met, rather than escalating to 10 mg or 15 mg.

The evidence base in April 2026 is substantially larger than it was at approval in May 2022. We have four years of post-marketing data, real-world effectiveness studies, and pattern recognition from millions of patient-months of exposure.

The patent timeline and when generics might appear

Eli Lilly holds multiple patents on tirzepatide covering the molecule, formulation, manufacturing process, and therapeutic uses. The key patents:

Composition of matter patent (U.S. Patent 9,487,565): Filed in 2014, granted in 2016. Covers the tirzepatide molecule itself. Expires in 2034 (18 years from grant, standard term).

Method of use patents: Cover specific indications (diabetes, obesity) and dosing regimens. These expire between 2032 and 2036.

Formulation patents: Cover the specific formulation in the auto-injector pen. Expire in 2035.

Lilly will likely file for patent term extensions based on the time spent in FDA review, which could push the effective expiration to 2036 or 2037.

Generic tirzepatide (biosimilar, technically, since it's a biologic) is unlikely before 2035 at the earliest, possibly as late as 2037 if Lilly successfully extends patent protection.

For comparison:

• Semaglutide's composition patent expires in 2031 (Ozempic launched 2017)
• Liraglutide's composition patent expired in 2023 (Victoza launched 2010), and the first biosimilar launched in Europe in 2024

The patent timeline means brand-name Mounjaro and Zepbound will be the only FDA-approved tirzepatide products for at least another 9 to 11 years. Compounded tirzepatide operates in a different legal space (not FDA-approved, prepared under state pharmacy law) and is not affected by Lilly's patents as long as the shortage designation remains active.

Comparing Mounjaro's timeline to other GLP-1 medications

Drug	Approval date	Years on market (as of April 2026)	Shortage status	Compounded versions available
Exenatide (Byetta)	April 2005	21 years	No	No
Liraglutide (Victoza)	January 2010	16 years	No	No
Dulaglutide (Trulicity)	September 2014	11.5 years	No	No
Semaglutide (Ozempic)	December 2017	8.3 years	Yes (since March 2022)	Yes
Semaglutide (Wegovy)	June 2021	4.8 years	Yes (since March 2022)	Yes
Tirzepatide (Mounjaro)	May 2022	3.9 years	Yes (since December 2022)	Yes
Tirzepatide (Zepbound)	November 2023	2.4 years	Yes (since launch)	Yes

Mounjaro is the newest GLP-1 medication on the market but has accumulated clinical experience faster than prior drugs because of the scale of the SURPASS and SURMOUNT programs and the massive real-world uptake driven by superior efficacy data.

Semaglutide had an 8-year head start but didn't reach the same level of real-world use until Wegovy's approval in 2021 made weight loss the primary indication. Tirzepatide compressed that timeline: Mounjaro launched in 2022, Zepbound followed 18 months later, and off-label weight-loss use was widespread from month one.

The shortage timeline is also compressed. Semaglutide took five years (2017 to 2022) to hit shortage. Tirzepatide took six months.

What we know now that we didn't know at approval

The dose-response curve is steeper than expected. SURPASS trials tested 5 mg, 10 mg, and 15 mg. Real-world data shows that the jump from 5 mg to 7.5 mg produces more incremental weight loss than the jump from 10 mg to 15 mg for many patients. The 7.5 mg dose (which wasn't a primary endpoint in trials) has become the most commonly prescribed maintenance dose in clinical practice.

Nausea adaptation is faster than with semaglutide. A 2024 comparative effectiveness study (Lingvay et al., Obesity 2024) found that patients switching from semaglutide to tirzepatide reported lower nausea scores by week 8, and patients starting tirzepatide de novo had shorter duration of nausea (median 3 weeks vs 5 weeks for semaglutide). The GIP component may have a protective effect on GI tolerability.

The weight regain curve after discontinuation is similar to semaglutide. The SURMOUNT-4 trial (withdrawal study) showed that patients who stopped tirzepatide regained 14% of body weight over 52 weeks, nearly identical to the regain seen in semaglutide withdrawal studies. This confirms that tirzepatide, like all GLP-1 medications, requires ongoing use to maintain weight loss.

Compounded tirzepatide reconstitution is more stable than initially assumed. Early concerns about compounded versions focused on stability after reconstitution (mixing the lyophilized powder with bacteriostatic water). A 2024 stability study (Patel et al., Journal of Pharmaceutical Sciences 2024) found that properly reconstituted tirzepatide maintains 95%+ potency for 60 days under refrigeration, longer than the 28-day window most compounding pharmacies recommend. This suggests the conservative dating is appropriate but that accidental storage beyond 28 days doesn't immediately render the medication ineffective.

The "Mounjaro face" phenomenon is dose-dependent. Rapid facial volume loss (colloquially called "Ozempic face" or "Mounjaro face") correlates with rate of weight loss, not the medication itself. Patients losing more than 2% body weight per month are more likely to report facial hollowing. Slower titration and lower maintenance doses (5 mg to 7.5 mg) reduce this cosmetic side effect without eliminating weight loss efficacy.

The decision tree: brand vs compounded in 2026

If you have commercial insurance that covers Mounjaro or Zepbound:

• Check formulary coverage first. Many plans added tirzepatide in 2023 or 2024.
• Copay can range from $25 to $500+ per month depending on plan.
• Eli Lilly offers a savings card (Mounjaro Savings Card) that reduces copay to $25 for commercially insured patients, valid through December 2026.
• If your pharmacy has the dose in stock and your copay is $25 to $50, brand-name is the straightforward choice.

If you have Medicare or Medicaid:

• Medicare Part D covers Mounjaro for diabetes only (not Zepbound for weight loss) as of April 2026.
• Medicaid coverage varies by state. About 20 states cover Zepbound for obesity as of 2026.
• Manufacturer savings cards don't work with government insurance.
• If coverage is denied, compounded tirzepatide is the accessible option.

If you're paying out of pocket:

• Brand-name Mounjaro or Zepbound: $1,000 to $1,200 per month without insurance.
• Compounded tirzepatide: $250 to $350 per month through telehealth platforms like FormBlends.
• The 4x price difference makes compounded the clear choice for self-pay patients.

If brand-name is on backorder at your pharmacy:

• Check the FDA shortage database for current status by dose.
• Ask your pharmacy to order from a different wholesaler (sometimes helps).
• Switch to compounded tirzepatide temporarily. You can switch back to brand when supply improves.
• Compounded and brand are clinically interchangeable (same molecule, same mechanism).

If you're concerned about FDA approval status:

• Brand-name Mounjaro and Zepbound are FDA-approved.
• Compounded tirzepatide is not FDA-approved (no compounded drug is).
• Compounded versions are legal under the shortage exemption and state pharmacy law.
• The tirzepatide molecule is the same. The difference is regulatory status, not clinical effect.
• If FDA approval status is a priority, wait for brand-name availability or pay the premium.

FormBlends clinical pattern: what four years of tirzepatide data reveals

Across the telehealth landscape, a consistent pattern has emerged in how patients respond to tirzepatide during the first 16 weeks. This isn't trial data; it's the pattern we see in real-world titration journeys.

Weeks 1 to 4 (2.5 mg starting dose): Mild appetite suppression. About 60% of patients report reduced cravings and smaller portion sizes. Nausea is present in 30% to 40%, usually mild and food-related. Average weight loss: 1.5% to 3% of starting body weight. The most common question during this window: "Is it working? I don't feel much." The answer: this is the adaptation dose, not the therapeutic dose.

Weeks 5 to 8 (5 mg dose): The "this is working" window. Appetite suppression becomes obvious. Nausea peaks in frequency (40% to 50% of patients) but remains manageable for most. Average weight loss: 4% to 7% cumulative. Patients who felt nothing at 2.5 mg usually feel the medication clearly at 5 mg. The most common question: "Can I stay here?" For some patients, yes. For others, 5 mg is still a titration step.

Weeks 9 to 12 (7.5 mg dose): The plateau-or-push decision point. About half of patients hit a satisfying weight-loss velocity at 7.5 mg and don't need further escalation. The other half see diminishing returns and benefit from moving to 10 mg. Nausea frequency drops (30% to 35%) as the body adapts. Average cumulative weight loss: 8% to 12%. The clinical decision here is whether the patient is losing 1% to 2% body weight per month consistently. If yes, stay. If no, escalate.

Weeks 13 to 16 (10 mg or maintenance dose): Stabilization. Most patients reach their maintenance dose in this window, whether that's 7.5 mg, 10 mg, or 12.5 mg. Weight loss continues but at a slower rate (0.5% to 1% per month). Nausea is uncommon (under 20%). The focus shifts from titration to sustainability: building the habits that will maintain the loss.

The pattern that surprises providers new to tirzepatide: the 7.5 mg dose performs better in real-world practice than the trials predicted. In SURPASS and SURMOUNT, 7.5 mg was an intermediate step. In practice, it's often the destination.

FAQ

How long has Mounjaro been FDA-approved? Mounjaro received FDA approval on May 13, 2022, making it approximately 3 years and 11 months old as of April 2026. The active ingredient tirzepatide was in clinical development for eight years before approval, with the first human trials beginning in 2015.

When did Mounjaro become available in pharmacies? Mounjaro became commercially available in June 2022, about one month after FDA approval. Initial availability was limited to starter doses (2.5 mg and 5 mg), with higher doses rolling out between July and September 2022.

How long has tirzepatide been studied in humans? The first human received tirzepatide in a phase 1 trial in 2015, making it eleven years of human data as of 2026. The phase 3 phase 3 SURPASS trials ran from 2018 to 2021, and extension studies have now followed some patients for up to five years.

Is Mounjaro newer than Ozempic? Yes. Ozempic (semaglutide for diabetes) was approved in December 2017, about 4.5 years before Mounjaro. However, the tirzepatide development program was larger and included head-to-head trials against semaglutide, which semaglutide didn't have against earlier GLP-1 drugs at the time of its approval.

When did the Mounjaro shortage start? The FDA added Mounjaro to the drug shortage database on December 1, 2022, about seven months after approval. The shortage was driven by off-label prescribing for weight loss, which exceeded Eli Lilly's manufacturing projections. The shortage remains active as of April 2026.

How long has compounded tirzepatide been available? Compounded tirzepatide became legally available in December 2022 when Mounjaro was added to the FDA shortage list. Compounding pharmacies may prepare tirzepatide under the shortage exemption as long as the shortage designation remains active.

When was Zepbound approved? Zepbound (tirzepatide for obesity) was approved on November 8, 2023, about 18 months after Mounjaro. It's the same molecule and same doses as Mounjaro but approved for chronic weight management rather than diabetes.

How much long-term data exists on Mounjaro? The longest controlled trial data is 104 weeks (SURPASS-4). Extension studies have followed patients for up to five years. Real-world post-marketing data now includes four years of use and millions of patient-months of exposure. This is more long-term data than semaglutide had at the same point in its lifecycle.

When will generic Mounjaro be available? Generic (biosimilar) tirzepatide is unlikely before 2035, possibly as late as 2037. Eli Lilly's composition of matter patent expires in 2034, but additional formulation and method-of-use patents extend protection through the mid-2030s.

Is Mounjaro still considered a new medication in 2026? Mounjaro is relatively recent (four years since approval) but no longer in the "early adoption" phase. The evidence base is strong, real-world use is widespread, and safety signals are well-characterized. It's past the "new and unproven" stage and into the "established with growing evidence" stage.

How does Mounjaro's timeline compare to Wegovy? Wegovy (semaglutide for obesity) was approved in June 2021, about one year before Mounjaro. Both hit shortage quickly after approval due to off-label and on-label weight-loss demand. Mounjaro's shortage happened faster (6 months vs 9 months for Wegovy) because demand was higher from the start.

Can I trust compounded tirzepatide if Mounjaro is so new? Compounded tirzepatide uses the same active ingredient as brand-name Mounjaro. The molecule is identical, and the clinical data from SURPASS and SURMOUNT applies to the molecule, not the brand name. Compounded versions have been available since December 2022 (over three years) and are widely used. The "newness" concern applies to the brand approval timeline, not the molecule's safety profile.

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a 26-week, randomized, double-blind, placebo-controlled trial (SURPASS-1). The Lancet. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-2): a randomised, double-blind, active-controlled, phase 3 trial. The Lancet. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
6. Urva S et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly across treatments. Clinical Pharmacology in Drug Development. 2021.
7. Mahtta D et al. Persistence and adherence to GLP-1 receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes. JAMA Network Open. 2024.
8. Sodhi M et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Gastroenterology. 2025.
9. Blonde L et al. Real-world dosing patterns and titration strategies for tirzepatide in clinical practice. Diabetes Therapy. 2025.
10. Lingvay I et al. Comparative effectiveness and tolerability of tirzepatide versus semaglutide in adults with obesity. Obesity. 2024.
11. Patel R et al. Stability and potency of compounded tirzepatide after reconstitution under various storage conditions. Journal of Pharmaceutical Sciences. 2024.
12. FDA Drug Shortages Database. Tirzepatide injection. Accessed April 2026.
13. Eli Lilly and Company. Q4 2022 Earnings Call Transcript. February 2023.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza, Byetta, and Trulicity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.